CFM
PDSB icon

Catalyst Funds Management’s PDS Biotechnology PDSB Stock Holding History

Catalyst Funds Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,600
Closed -$21.4K – 994
2024
Q3 		$21.4K Hold
5,600
– – ﹤0.01% 1066
2024
Q2 		$16.4K Buy
+5,600
New +$17.9K ﹤0.01% 746

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Catalyst Funds Management's PDSB Position: Q4 2024 in Review

Catalyst Funds Management sold out of PDS Biotechnology (PDSB) in Q4 2024, closing a stake of 5,600 shares — an estimated $21.4K sold.

Catalyst Funds Management first reported a position in PDSB in Q2 2024 and held it in 2 quarters. The position peaked at $21.4K in Q3 2024. 52 funds tracked by Wall St. Rank hold PDSB as of Q4 2024.

  • Catalyst Funds Management reported no remaining PDS Biotechnology position as of Q4 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 5,600 PDS Biotechnology shares in Q4 2024, an estimated $21.4K.
  • Catalyst Funds Management first reported a position in PDS Biotechnology in Q2 2024 and held it in 2 quarters.
  • Catalyst Funds Management's PDS Biotechnology position peaked at $21.4K in Q3 2024.
  • 52 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.